Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $812.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective upped by Sanford C. Bernstein from $756.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a market perform rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group increased their price objective on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Truist Financial lifted their target price on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Raymond James Financial increased their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Regeneron Pharmaceuticals Trading Down 4.4%

Shares of REGN stock opened at $930.67 on Monday. The stock has a market capitalization of $95.82 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 1.45 and a beta of 0.10. The company’s fifty day simple moving average is $800.69 and its two-hundred day simple moving average is $741.11. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $991.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same period last year, the company earned $11.83 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Insider Activity

In other news, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president owned 12,003 shares in the company, valued at $10,291,252.17. The trade was a 8.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 20,789 shares of company stock worth $18,766,698. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. State Street Corp increased its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Bank of America Corp DE lifted its stake in shares of Regeneron Pharmaceuticals by 2.8% in the 1st quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock valued at $919,120,000 after acquiring an additional 32,158 shares during the last quarter. Amundi lifted its stake in shares of Regeneron Pharmaceuticals by 27.5% in the 1st quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after acquiring an additional 217,892 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $473,872,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.